Results 71 to 80 of about 55,390 (294)

Življenje in znanstveno delo Milovana Gavazzija

open access: yesTraditiones, 1992
.
Vilko Novak
doaj  

»Hrvatska duhovna lirika« [PDF]

open access: yes, 1969
Prikaz knjige »Hrvatska duhovna lirika«, uredio ĐURO KOKŠA, Rim, 1968. Nakl.
Lončarević, Juraj
core  

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang   +12 more
wiley   +1 more source

Fomopsioza ili crna pjegavost vinove loze (Diaporthe neoviticola, syn. Phomopsis viticola)

open access: yesGlasnik Zaštite Bilja, 2021
Vinova loza je jedna od najvažnijih kultiviranih biljnih vrsta u Hrvatskoj. Vrsta je izrazito osjetljiva na napad velikog broja patogena, od kojih je i kod nas i u svijetu jedan od najvažnijih i najopasnijih Diaporthe neoviticola, odnosno fitopatogena ...
Tihomir Miličević
doaj  

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Hrvatska 2015

open access: yesHrvatska i komparativna javna uprava, 2016
U 2015. dolazi do postupnog gospodarskog oporavka što najavljuje izlazak iz šestogodišnje ekonomske recesije. To je zadnja godina mandata vlade lijevog centra predvođene Socijaldemokratskom partijom (SDP) pa je javni diskurs obilježen žučnim javnim debatama. Za razliku od 2014. i nesuglasica oko primjene europskog uhidbenog naloga, u 2015.
Koprić, Ivan, Škarica, Mihovil
openaire   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Matica hrvatska Award for Science [PDF]

open access: yes, 2011
The biographical lexicon Hrvatski kartografi (Croatian Cartographers) has been awarded by Matica hrvatska with Oton Kučera Award for scientific ...
Zorić, Damir, Damir Zorić
core  

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy